达拉图穆马布治疗"真正脆弱"的老年骨髓瘤患者
Yuichi Horigome1, Kazuhito Suzuki2, Takahiro Suzuki1,3
1Department of Hematology, Kitasato University Graduate School of Medical Sciences, Sagamihara 252-0373, Kanagawa, Japan.
Life (Basel, Switzerland)
|March 28, 2024
概括
脆弱的老年多发性髓瘤 (MM) 患者需要更好的治疗方法. 达拉图穆马布 (DARA) 对改善这一群体的结果和生活质量 (QOL) 是有前途的.
科学领域:
- 血液学 血液学 血液学
- 老年医学 老年医学
- 临床药房 临床药房
背景情况:
- 多发性骨髓瘤 (MM) 治疗结果有所改善,但脆弱的老年患者仍然缺乏服务.
- 老年MM人口和治疗复杂性正在增加,需要优化护理策略.
- 脆弱性评估对于分层老年MM患者和制定量身定制的治疗计划至关重要.
研究的目的:
- 对多发性骨髓瘤患者的现有脆弱性评估工具进行审查.
- 在脆弱的老年MM患者中重新审查达拉图穆马布 (DARA) 治疗方案的证据.
- 讨论管理脆弱的老年MM患者的潜在改善.
主要方法:
- 文献综述侧重于MM的脆弱性评估.
- 对老年MM患者DARA的临床试验数据和现实世界的证据的分析.
- 讨论治疗策略和质量生活考虑.
主要成果:
- 达拉图马布 (DARA) 治疗在脆弱的老年MM患者中显示出疗效和生活质量 (QOL) 的好处.
- 目前的脆弱性评估需要改进,以准确地分层患者.
- 优化DARA利用可以将好处扩展到更广泛的MM患者群体.
结论:
- 准确的脆弱性评估工具对于优化老年人MM治疗至关重要.
- 达拉图马布 (DARA) 为脆弱的老年MM患者提供了一种有价值的治疗选择,提高了生存率和QOL.
- 对创新的DARA应用程序进行进一步的研究是有必要的,以改善对这一弱势群体的护理.
更多相关视频
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.4K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:20Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K